ID

30393

Descripción

Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma; ODM derived from: https://clinicaltrials.gov/show/NCT00794261

Link

https://clinicaltrials.gov/show/NCT00794261

Palabras clave

Versiones (2)
  1. 1/6/18 1/6/18 -
  2. 1/6/18 1/6/18 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

1 de junio de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Lymphoma NCT00794261

Inglés

Eligibility Lymphoma NCT00794261

1 formularios  
  1. StudyEvent: Eligibility
    1. Eligibility Lymphoma NCT00794261
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
male or female patients aged ≥ 18 years
Descripción

Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
patients with histologically confirmed lymphoma or myeloma
Descripción

Lymphoma | Multiple Myeloma

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0024299
UMLS CUI [2]
C0026764
treatment with high-dose chemotherapy before inclusion
Descripción

High-dose chemotherapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1328050
intensification with high dose melphalan for patients with myeloma
Descripción

Melphalan High dose | Multiple Myeloma

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0025241
UMLS CUI [1,2]
C0444956
UMLS CUI [2]
C0026764
whatever the conditioning regimen, except tbi for patients with 1st relapse of hodgkin's lymphoma or with mnhl nb: patients having received two intensification courses are eligible if there has been more than 100 days between courses.
Descripción

Transplantation Conditioning | Exception Whole-Body Irradiation First Relapse Hodgkin Disease | Other Coding | Consolidation therapy Quantity

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0376450
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0043162
UMLS CUI [2,3]
C4054953
UMLS CUI [2,4]
C0019829
UMLS CUI [3]
C3846158
UMLS CUI [4,1]
C1511484
UMLS CUI [4,2]
C1265611
autologous psc transplantation at the time of inclusion
Descripción

Primary sclerosing cholangitis Autologous Transplantation

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0566602
UMLS CUI [1,2]
C0040736
reinjection of ≥ 2.106 cd34/kg
Descripción

Reinjection CD34 stem cell count

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0444600
UMLS CUI [1,2]
C1277788
patients hospitalized in the investigator center throughout the procedure until recovery from aplasia (pnn > 0.5 g/l)
Descripción

Hospitalization | Aplasia Recovery | Polymorphonuclear neutrophil Count

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0019993
UMLS CUI [2,1]
C0243065
UMLS CUI [2,2]
C2004454
UMLS CUI [3,1]
C0027950
UMLS CUI [3,2]
C0750480
mandatory affiliation with a health insurance system
Descripción

Affiliation mandatory Health Insurance

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1510825
UMLS CUI [1,2]
C1514873
UMLS CUI [1,3]
C0021682
patients able to understand, read and write french
Descripción

Comprehension French language | Able to read French language | Able to write French language

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0233733
UMLS CUI [1,2]
C0376246
UMLS CUI [2,1]
C0586740
UMLS CUI [2,2]
C0376246
UMLS CUI [3,1]
C0584993
UMLS CUI [3,2]
C0376246
signed, written informed consent
Descripción

Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
tbi during conditioning
Descripción

Whole-Body Irradiation During Conditioning

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0043162
UMLS CUI [1,2]
C0347984
UMLS CUI [1,3]
C0376450
severe intolerance to the growth factor under study, or hypersensitivity to one of their components
Descripción

Intolerance Severe Growth Factor Study | Intolerance Severe Growth Factor Component

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0231199
UMLS CUI [1,2]
C0205082
UMLS CUI [1,3]
C0018284
UMLS CUI [1,4]
C2603343
UMLS CUI [2,1]
C0231199
UMLS CUI [2,2]
C0205082
UMLS CUI [2,3]
C0018284
UMLS CUI [2,4]
C1705248
immunosuppressive syndrome
Descripción

Immunosuppression

Tipo de datos

boolean

Alias
UMLS CUI [1]
C4048329
pregnant or lactating women
Descripción

Pregnancy | Breast Feeding

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
difficult follow-up
Descripción

Follow-up Difficult

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3274571
UMLS CUI [1,2]
C0332218
documented history of cognitive or psychiatric disorders
Descripción

Cognition Disorders | Mental disorders

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0009241
UMLS CUI [2]
C0004936
participation or consideration of participation in another biomedical study during the follow-up period of the present trial.
Descripción

Study Subject Participation Status | Biomedical Research | Consideration Participation Biomedical Research

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0005540
UMLS CUI [3,1]
C0518609
UMLS CUI [3,2]
C0679823
UMLS CUI [3,3]
C0005540
Volver a la parte superior de la página

Similar models

Eligibility Lymphoma NCT00794261

1 formularios
  1. StudyEvent: Eligibility
    1. Eligibility Lymphoma NCT00794261
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
male or female patients aged ≥ 18 years
boolean
C0001779 (UMLS CUI [1])
Lymphoma | Multiple Myeloma
Item
patients with histologically confirmed lymphoma or myeloma
boolean
C0024299 (UMLS CUI [1])
C0026764 (UMLS CUI [2])
High-dose chemotherapy
Item
treatment with high-dose chemotherapy before inclusion
boolean
C1328050 (UMLS CUI [1])
Melphalan High dose | Multiple Myeloma
Item
intensification with high dose melphalan for patients with myeloma
boolean
C0025241 (UMLS CUI [1,1])
C0444956 (UMLS CUI [1,2])
C0026764 (UMLS CUI [2])
Transplantation Conditioning | Exception Whole-Body Irradiation First Relapse Hodgkin Disease | Other Coding | Consolidation therapy Quantity
Item
whatever the conditioning regimen, except tbi for patients with 1st relapse of hodgkin's lymphoma or with mnhl nb: patients having received two intensification courses are eligible if there has been more than 100 days between courses.
boolean
C0376450 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0043162 (UMLS CUI [2,2])
C4054953 (UMLS CUI [2,3])
C0019829 (UMLS CUI [2,4])
C3846158 (UMLS CUI [3])
C1511484 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
Primary sclerosing cholangitis Autologous Transplantation
Item
autologous psc transplantation at the time of inclusion
boolean
C0566602 (UMLS CUI [1,1])
C0040736 (UMLS CUI [1,2])
Reinjection CD34 stem cell count
Item
reinjection of ≥ 2.106 cd34/kg
boolean
C0444600 (UMLS CUI [1,1])
C1277788 (UMLS CUI [1,2])
Hospitalization | Aplasia Recovery | Polymorphonuclear neutrophil Count
Item
patients hospitalized in the investigator center throughout the procedure until recovery from aplasia (pnn > 0.5 g/l)
boolean
C0019993 (UMLS CUI [1])
C0243065 (UMLS CUI [2,1])
C2004454 (UMLS CUI [2,2])
C0027950 (UMLS CUI [3,1])
C0750480 (UMLS CUI [3,2])
Affiliation mandatory Health Insurance
Item
mandatory affiliation with a health insurance system
boolean
C1510825 (UMLS CUI [1,1])
C1514873 (UMLS CUI [1,2])
C0021682 (UMLS CUI [1,3])
Comprehension French language | Able to read French language | Able to write French language
Item
patients able to understand, read and write french
boolean
C0233733 (UMLS CUI [1,1])
C0376246 (UMLS CUI [1,2])
C0586740 (UMLS CUI [2,1])
C0376246 (UMLS CUI [2,2])
C0584993 (UMLS CUI [3,1])
C0376246 (UMLS CUI [3,2])
Informed Consent
Item
signed, written informed consent
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Whole-Body Irradiation During Conditioning
Item
tbi during conditioning
boolean
C0043162 (UMLS CUI [1,1])
C0347984 (UMLS CUI [1,2])
C0376450 (UMLS CUI [1,3])
Intolerance Severe Growth Factor Study | Intolerance Severe Growth Factor Component
Item
severe intolerance to the growth factor under study, or hypersensitivity to one of their components
boolean
C0231199 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0018284 (UMLS CUI [1,3])
C2603343 (UMLS CUI [1,4])
C0231199 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0018284 (UMLS CUI [2,3])
C1705248 (UMLS CUI [2,4])
Immunosuppression
Item
immunosuppressive syndrome
boolean
C4048329 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
pregnant or lactating women
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Follow-up Difficult
Item
difficult follow-up
boolean
C3274571 (UMLS CUI [1,1])
C0332218 (UMLS CUI [1,2])
Cognition Disorders | Mental disorders
Item
documented history of cognitive or psychiatric disorders
boolean
C0009241 (UMLS CUI [1])
C0004936 (UMLS CUI [2])
Study Subject Participation Status | Biomedical Research | Consideration Participation Biomedical Research
Item
participation or consideration of participation in another biomedical study during the follow-up period of the present trial.
boolean
C2348568 (UMLS CUI [1])
C0005540 (UMLS CUI [2])
C0518609 (UMLS CUI [3,1])
C0679823 (UMLS CUI [3,2])
C0005540 (UMLS CUI [3,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial